Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
7 hedge funds and large institutions have $149K invested in Plus Therapeutics in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
27% more capital invested
Capital invested by funds: $117K → $149K (+$32K)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$42.3K |
| 2 |
VF
Virtu Financial
New York
|
+$31.7K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$5.28K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$26.4K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$5K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $88K | +$42.3K | +8 | +80% |
|
|
VF
2
Virtu Financial
New York
| $36K | +$31.7K | +6 | +300% |
|
3
BlackRock
New York
| $6K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $6K | +$5.28K | +1 | New |
|
|
5
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $5K | +$5.28K | +1 | New |
|
6
Geode Capital Management
Boston,
Massachusetts
| $4K | – | – | – |
|
|
MOS
7
MGO One Seven
Beachwood,
Ohio
| $2K | – | – | – |
|
|
LTFS
8
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
9
Morgan Stanley
New York
| $1K | – | – | – |
|
|
FDCDDQ
10
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $3 | – | – | – |
|
|
11
Barclays
London,
United Kingdom
| – | -$26.4K | -5 | Closed |
|
|
PCM
12
Perkins Capital Management
Wayzata,
Minnesota
| – | -$5K | -1 | Closed |
|
|
13
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$2K | – | – |
|
PSTV Hedge Fund Activity: Q1 2019 in Review
7 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2019, worth a combined $149K — up 27% from $117K a quarter earlier.
Fund positioning in PSTV was balanced in Q1 2019: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $42.3K. The largest seller was Barclays, exiting entirely with an estimated $26.4K sold.
- 7 institutional investors held Plus Therapeutics (PSTV) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $149K of Plus Therapeutics stock for Q1 2019, up 27% quarter-over-quarter.
- 2 funds opened new Plus Therapeutics positions in Q1 2019 and 2 closed out, a net change of 0 holders.
- The largest Plus Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $42.3K added.
- The largest Plus Therapeutics seller in Q1 2019 was Barclays, an estimated $26.4K sold.
Based on aggregated 13F filings for Q1 2019.